Business Wire

LFB Announces FDA Approval of SEVENFACT®, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors

Share

LFB today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) 2061 for SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw], for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with Hemophilia A or B with inhibitors (neutralizing antibodies). An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.

Denis Delval LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the FDA approval of SEVENFACT® which provides a new treatment option for hemophilia patients. This approval is a validation of an innovative LFB technology. We will now work towards SEVENFACT® registration in Europe and other core countries, in order to offer this therapeutic option to patients.”

Hemophilia A or B

Hemophilia A or B is a congenital bleeding disorder caused by a dysfunction or deficiency of Coagulation Factor (F) VIII or IX, respectively. People with Hemophilia may bleed for a longer time than others after injury or surgery. They may also have spontaneous bleeding in muscles, joints and organs, which may be life-threatening. Individuals with inhibitors may not respond to factor replacement therapy. According to the Centers for Disease Control and Prevention (CDC), there are an estimated 20,000 people living with Hemophilia in the United States1. Bleeding episodes in these individuals are managed by either on-demand treatment or prophylaxis using products containing FVIII or FIX. However, when inhibitors to FVIII or FIX develop in these individuals, treatment of bleeding episodes with FVIII or FIX products may no longer be effective. In these situations, the administration of products such as SEVENFACT®, which bypass the Factor VIII and Factor IX that are blocked by inhibitors, promotes clot formation and controls bleeding.

About SEVENFACT®

SEVENFACT® is an innovative recombinant form of human Factor VIIa (rhFVIIa). This new biological entity is manufactured using LFB’s proprietary and state of the art rPRO™ technology.

The safety and efficacy of SEVENFACT® were determined using data from a clinical study that evaluated 27 patients with hemophilia A or B with inhibitors, which included treatment of 465 mild or moderate, and three severe bleeding episodes. The study assessed the efficacy of treatment 12 hours after the initial dose was given. The proportion of mild or moderate bleeding episodes treated successfully both with the lower dose of 75mcg/kg and higher dose of 225 mcg/kg (requiring no further treatment for the bleeding episode, no administration of blood products and no increase in pain beyond 12 hours from initial dose) was approximately 86%. The study also included three severe bleeding episodes that were treated successfully with the higher dose.

Another study evaluated the safety and pharmacokinetics of three escalating doses of SEVENFACT® in 15 patients with severe hemophilia A or B with or without inhibitors. Results from this study were used to select the two doses, 75mcg/kg and 225 mcg/kg, that were evaluated in the study described above.

The most common side effects of SEVENFACT® were headache, dizziness, infusion-site discomfort, infusion-related reaction, infusion-site hematoma, and fever.

Serious arterial and venous thrombotic events may occur following administration of SEVENFACT®. There is limited information about the safety of SEVENFACT® in patients with a history of arterial or venous thromboembolic disease, because such patients were excluded from SEVENFACT® trials.

SEVENFACT® is contraindicated in patients with known allergy or hypersensitivity to rabbits or rabbit proteins.

For more information, please see the FDA news release: https://www.fda.gov/news-events/press-announcements/fda-approves-additional-treatment-adults-and-adolescents-hemophilia-or-b-and-inhibitors

About LFB
LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals, with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care.
LFB currently markets 15 products in more than 30 countries.
Please visit
www.groupe-lfb.comfor additional information.

About HEMA Biologics, LLC
HEMA Biologics is a biopharmaceutical company, located in Louisville, KY. HEMA Biologics has commercialization and distribution rights for SEVENFACT® in the U.S. and Canada. HEMA Biologics takes pride in the heritage of LFB, the developer and manufacturer of SEVENFACT®.
The company is dedicated to meeting the needs of patients living with rare bleeding disorders, supporting the community that cares for them, and bringing meaningful products and services to the marketplace to help improve their daily lives.
Please visit https://hemabio.com/ for additional information.

1 Source https://www.cdc.gov/ncbddd/hemophilia/data.html

Contact information

LFB Contacts (France):
Didier Véron - Executive VP Corporate Affairs
Tel: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54
verondidier@lfb.fr

HEMA Biologics Contacts:
For information contact:
Call: 855.718.HEMA (4362)
Fax: 855.721.HEMA (4362)
medinfo@hemabio.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix Wins TV Technology’s Best of Show for VCAS 5 for DVB26.5.2020 17:45:00 CESTPress release

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that its VCAS™ 5 for DVB solution is a winner of the 2020 Future Best of Show Awards, presented by TV Technology. The award recognizes VCAS 5 for DVB – a powerful, re-engineered version of its VCAS for DVB Broadcast security solution – as an outstanding new product. “Despite not being able to debut VCAS 5 for DVB at NAB Show, we are thrilled for it to receive such a positive reception by the industry experts who served on Future’s Best of Show Awards panel of judges,” commented Asaf Ashkenazi, COO of Verimatrix. “What makes the next-generation solution stand out is not just its ability to provide the highest level of broadcast security available today, but also its ability to do so while benefitting operators with improved speed, adaptability, scalability and cost savings – as well as a reliable end-user experience.” In April, Verimatrix announced it had f

Mary Kay Unveils Groundbreaking Research During Skin of Color Society Virtual Program26.5.2020 17:32:00 CESTPress release

Mary Kay Inc., a leader in skin care innovation for more than 56 years, continued its ongoing support of the beauty and scientific communities by presenting findings during the 2020 Skin of Color Society Symposium Virtual Program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005633/en/ Dr. Lucy Gildea, Chief Scientific Officer of Mary Kay (Photo: Mary Kay Inc.) Dr. Cristi Gomez, Director, Product Safety & Environmental Toxicology, revealed new research on the science behind LumiVie, an intensive serum by Mary Kay that brightens, energizes and moisturizes skin. As urbanization increases globally, the effects of pollution on skin is a growing concern. Chronic exposure to air pollution has been correlated with visible aging—in particular, the development of pigment spots. Researchers at Mary Kay developed a skincare formulation containing botanical extracts and vitamins B3 and C that is both suitable for sensitive skin

Jefferies to Hold Global Coronavirus Relief Charity Day Dedicated to the Memory of Peg Broadbent on May 27th26.5.2020 17:17:00 CESTPress release

Jefferies confirmed today that it will hold a Global Coronavirus Relief Charity Day tomorrow, Wednesday, May 27, 2020. The firm and its staff will contribute to global charities and relief efforts to assist those suffering from the devastation caused by the Coronavirus global pandemic and will offer investors around the world the opportunity to join these efforts by trading with Jefferies. Jefferies will dedicate this entire effort to their late CFO Peg Broadbent, who was a victim of this terrible disease. As previously announced, Jefferies will donate net commissions from trading on May 27 for all global trading in equities, fixed income and foreign exchange by the firm’s clients. In addition, Jefferies as a firm will donate $1 million directly, and all 3,822 employees worldwide will be given the opportunity to donate to these efforts. These contributions will be allocated to a series of charities on the front lines in fighting this ongoing global pandemic and providing urgently neede

New Automated Optical Inspection from Nordson EFD Verifies Fluid Deposit Placement and Accuracy26.5.2020 16:26:00 CESTPress release

Nordson EFD, a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, introduces OptiSure™ Automated Optical Inspection (AOI) software and confocal laser as add-ons to its existing vision-guided dispensing robots. OptiSure AOI add-ons provide optical assurance of fluid deposit accuracy and integrate seamlessly with Nordson EFD’s proprietary DispenseMotion™ software. Using robots’ existing vision systems to verify fluid deposit widths and diameters, the AOI software determines if dispense requirements have been met. Constant closed-loop feedback provides automated quality control (QC) data, saving manufacturers time and cost. “Optical assurance of fluid deposit accuracy in an off-the-shelf solution is a game changer for our customers,” said Johnathan Titone, global product line manager for automated dispensing systems, Nordson EFD. “We saw a need in the market to integrate automated dispensing and AOI and we’re pleased to provide a market-le

LTI Wins 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year26.5.2020 16:13:00 CESTPress release

Larsen & Toubro Infotech (BSE code: 540005, NSE: LTI), a global technology consulting and digital solutions company, has won the 2020 SAP® Pinnacle Award as the Industry Innovation Partner of the Year. This award recognizes LTI’s contribution to delivering best-in-class industry solutions that complement the industry portfolio from SAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005562/en/ LTI has a long-term relationship with SAP, spanning over 20 years, and is uniquely positioned as a partner, co-Innovator and customer. LTI is a Global Strategic Services Partner, and this partnership enables its participation in the SAP S/4HANA® Movement program to promote and accelerate adoption of SAP S/4HANA. In addition, this partnership enables LTI to work closely with SAP’s industry teams to deliver transformational industry specific solutions such as its Intelligent Construction Enterprise. With its deep industry expertise

Rockwell Automation Issues 2019 Corporate Responsibility Report and Launches New Online Hub for Corporate Responsibility and Sustainability Content26.5.2020 16:00:00 CESTPress release

Rockwell Automation, Inc. (NYSE: ROK), today announced the launch of the annual Corporate Responsibility Report (CRR), highlighting the company’s efforts during 2019. The CRR reflects Rockwell Automation’s commitment to placing corporate responsibility and sustainability practices at the core of its approach to customers, employees, and communities. A global industrial automation and digital transformation leader, Rockwell Automation aims to be a principal voice in the corporate responsibility and sustainability space. The 2019 CRR highlights the company’s successful initiatives to continue to build a more inclusive workplace for employees; help customers reduce emissions and waste; and be a catalyst for progress in local communities. In conjunction with the publication of the 2019 CRR, Rockwell Automation today launched a new corporate responsibility content hub. Rockwell Automation’s corporate responsibility content hub will feature new stories and updates on its corporate responsibi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom